Table 2.
Osteoporosis-related patient history and medication use
| Characteristic | Overall | US | Canada |
|---|---|---|---|
| N = 935 | N = 632 | N = 303 | |
| Any history of fracture, n (%) | 525 (56.1) | 361 (57.1) | 164 (54.1) |
| Osteoporotic fracture, n (%)a | 468 (50.1) | 324 (51.3) | 144 (47.5) |
| Vertebral | 149 (15.9) | 104 (16.5) | 45 (14.9) |
| Nonvertebral | 389 (41.6) | 270 (42.7) | 119 (39.3) |
| Major nonvertebralb | 261 (27.9) | 178 (28.2) | 83 (27.4) |
| Hip | 61 (6.5) | 46 (7.3) | 15 (5.0) |
| More than one fracture, n (%) | 246 (26.3) | 173 (27.4) | 73 (24.1) |
| Time since the most recent fractures, n (%) | |||
| <12 months | 67 (7.2) | 39 (6.2) | 28 (9.2) |
| ≥12 months | 456 (48.8) | 320 (50.6) | 136 (44.9) |
| Parent had hip fracture, n (%) | 196 (21.0) | 127 (20.1) | 69 (22.8) |
| Osteoporosis medication | |||
| Any exposure to prior prescription osteoporosis therapy prior to enrollment, n (%) | 867 (92.7) | 587 (92.9) | 280 (92.4) |
| Exposure to prior prescription osteoporosis therapy during the period >5 years prior to enrollment, n (%) | 547 (58.5) | 360 (57.0) | 187 (61.7) |
| Number of prior osteoporosis medications taken, mean (SD) | 2.0 (1.3) | 2.0 (1.3) | 2.0 (1.2) |
| Osteoporosis medications prescribed in the last 5 years, n (%) | |||
| Alendronate | 398 (42.6) | 255 (40.3) | 143 (47.2) |
| Calcium supplements and vitamin D supplements | 376 (40.2) | 232 (36.7) | 144 (47.5) |
| Risedronate | 294 (31.4) | 167 (26.4) | 127 (41.9) |
| Zoledronic acid | 168 (18.0) | 123 (19.5) | 45 (14.9) |
| PTH/Teriparatide | 163 (17.4) | 150 (23.7) | 13 (4.3) |
| Ibandronate | 128 (13.7) | 128 (20.3) | 0 (0.0) |
| Hormone replacement therapy | 45 (4.8) | 24 (3.8) | 21 (6.9) |
| Raloxifene | 42 (4.5) | 27 (4.3) | 15 (5.0) |
| Other (non-bisphosphonate) | 31 (3.3) | 26 (4.1) | 5 (1.7) |
| Etidronate | 28 (3.0) | 0 (0.0) | 28 (9.2) |
| Calcitonin | 28 (3.0) | 16 (2.5) | 12 (4.0) |
| Other bisphosphonate | 6 (0.6) | 3 (0.5) | 3 (1.0) |
| Strontium ranelate | 2 (0.2) | 0 (0.0) | 2 (0.7) |
PTH parathyroid hormone, SERM selective estrogen receptor modulator, SD standard deviation, US United States
aAny fracture recorded on the case report form, excluding skull, facial bones, mandible, metacarpus, finger phalanges, toe phalanges, and cervical vertebrae and not associated with known severe trauma (fall from higher than the height of stool, chair, first rung on a ladder or equivalent [>20 in], or severe trauma other than a fall) or pathological fractures
bA subset of nonvertebral fractures including the following locations: pelvis, hip, lower leg (not knee or ankle), ribs, shoulder, forearm, and wrist and not associated with known severe trauma or pathological fractures